ClinicalTrials.gg
RecruitingNCT05793151ENDUREUpdated Dec 11, 2025

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

An interventional study of ENDURE in Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma and Oropharynx Cancer, sponsored by Medical University of South Carolina. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Head and Neck Neoplasms by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Head and Neck Neoplasms · Medical University of South Carolina.

Planned enrollment
Largest of 15
532 · median 30
Started
2023
with 2 others
No phase
12 of 17
5 open now
Registered
14th of 17
by date

Among the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 14th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are:

  1. Does ENDURE improve initiation of timely PORT relative to treatment as usual?
  2. What are the mechanisms through which ENDURE improves timeliness to treatment?
  3. What are the barriers and facilitators to the implementation of ENDURE into routine clinical care?
Read the detailed description

In this hybrid type 1 effectiveness-implementation study, the investigators will conduct a stepped-wedge cluster randomized trial with cancer centers (n=4; 484 patients) randomized to sequentially deliver treatment as usual (TAU) then ENDURE to patients with head and neck cancer undergoing surgery and postoperative radiation therapy (PORT). The trial will assess the effect of ENDURE vs TAU on improving initiation of timely PORT (primary objective) and the underlying mechanisms of ENDURE (secondary objective). The investigators will concurrently conduct a mixed-methods study with quantitative measures of implementation outcomes and qualitative data about implementation determinants from semi-structured interviews with key stakeholders and site visits (exploratory objective).

03

Conditions studied

  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Oropharynx Cancer
  • Oral Cavity Cancer
  • Larynx Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >/= 18 years
  2. Squamous cell carcinoma (SCC) (or histologic variant) of the oral cavity, oropharynx, hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity
  3. American Joint Committee on Cancer (AJCC) 8th edition clinical T3-4 or >N1 SCC of the oral cavity, oropharynx, hypopharynx, larynx, paranasal sinuses, nasal cavity, or unknown primary.
  4. No history of radiation therapy for treatment of HNSCC in the definitive or settings that would, at the discretion of the enrolling clinician, affect the patient's need for adjuvant RT.
  5. Plan for curative intent surgery at one of the participating centers
  6. Plan for PORT (regardless of whether it is at the surgical center) with or without concurrent chemotherapy following curative intent surgery based on the expectation of at least one of the following adverse features on final pathologic evaluation: pT3 or pT4 primary, N1 or greater nodal disease, perineural invasion (PNI), or lymphovascular invasion (LVI).

Exclusion criteria

Exclusion Criteria:

  1. Inability to speak or read English or Spanish.
  2. Severe mental illness that would prevent trial participation.
  3. HPV-positive OPC or unknown primary SCC staged as cT1-2N1 with a single ipsilateral LN \< 3 cm
  4. Synchronous untreated expected to impact
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
532 participants (estimated)

Study arms

  • Experimental
    ENDURE

    ENDURE is a theoretically-informed, navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT.

    Behavioral: ENDURE

  • No intervention
    Treatment As Usual

    Treatment as usual at each site consists of standard of care clinical practices

Interventions

  • BehavioralENDURE

    ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.

06

What researchers measure

Primary outcomes

  1. Initiation of Timely PORT

    The initiation of PORT \> 6 weeks (42 days) following definitive surgery for HNSCC.

    Time frame: 3 months

Secondary outcomes

  1. Time-to-PORT

    The number of days from the date of definitive surgery for HNSCC to the date of initiation of PORT.

    Time frame: 4 months

  2. Pre-Surgical consultation with radiation oncology

    Consultation with a treating radiation oncologist prior to definitive surgery for HNSCC.

    Time frame: 1 month

  3. Pre-radiation therapy dental extractions

    The removal of indicated carious/non-restorable teeth prior to or during the surgery for HNSCC.

    Time frame: 1 month

  4. Time to postoperative scheduling with radiation oncology

    The time from definitive surgery to the placement of the postoperative referral (or follow-up appointment) with the treating radiation oncologist.

    Time frame: 3 months

  5. Time to postoperative appointment with radiation oncology

    Time from definitive surgery to the attendance at an appointment with the treating radiation oncologist.

    Time frame: 3 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Below are the key elements of the data sharing plan as outlined in the NIH Policy for Data Management and Sharing: Research materials will include: (1) self-report measures from patients; (2) clinical data from the electronic medical record; (3) audio recordings and transcriptions of interviews from stakeholders; and (4) field notes from direct observations of the delivery of ENDURE at each site. Data will be raw or minimally processed. The investigators plan to use REDCap for data capture and management of the clinical and self-report measure data and NVivo for management of the qualitative data. REDCap data dictionaries can be distributed for reuse. The final data dictionaries have not been developed. Scientific data and metadata will be generated, preserved, and shared using NIH common data elements. Scientific data and metadata arising from the project will be uploaded to openICPSR, a self-publishing repository for social, behavioral, and health sciences research data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be shared no later than the time of a publication of findings of the trial's primary endpoint in a peer-reviewed journal.

Access criteria: All data sharing will comply with privacy and confidentiality protections such as the NIH Certificate of Confidentiality and applicable laws, regulations, and policies governing data derived from human participants.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2028, 53 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 53 months is above that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Mar 31, 2023
StartActual
Oct 30, 2023
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 30, 2028
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05793151
Responsible party
Evan Graboyes (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Mar 31, 2023
Start date
Oct 30, 2023
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Dec 11, 2025

Study contacts

Evan M Graboyes, MD, MPH
Contact
graboyes@musc.edu
843-792-0719
Evan M Graboyes, MD, MPH
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion